

REFERENCES

- Ahmadzadeh, A. and Derakhshan, A. (2008):** A clinicopathological study of lupus nephritis in children. Saudi. J. Kidney Dis. Transpl; 19: 756-760.
- Ahn, S.Y. and Ingulli, E. (2008):** Acute post streptococcal glomerulonephritis: an update. Curr. Opin. Pediatr. Apr; 20(2): 157-62.
- Alarcon-Segovia, D., Tumlin, J. A., Furie, R. A., McKay, J. D., Cardiel, M.H. and Strand, V., (2003):** LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum; 48(2): 442-454.
- Anthony, B.F., Kaplan, E.L. and Wannamaker, L.W. (1969):** Attack rates of acute nephritis after type 49 streptococcal infections of the skin and of the respiratory tract. J. Clin. Invest; 48: 1697-704.
- Appel, G.B. and Valeri, A. (1994):** The course and treatment of lupus nephritis. Annu. Rev. Med; 45: 525-537.
- Appel, G.B., Cohen, D.J., Pirani, C.L., Meltzer, J.I. and Estes, D. (1987):** Long-term Follow -up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am. J. Med; 83(5): 877-885.
- Appenzeller, S., Blatyta, P.F. and Costallat, L.T. (2008):** Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol. Int; 28(6): 567-571.

- Aranow, C. and Ginzler, E.M. (2000):** Epidemiology of cardiovascular disease in systemic lupus erythematosus. *Lupus*; 9(3): 166-169.
- Ardiles, L.G., Valderrama, G. and Moya, P. (1997):** Incidence and studies on antigenic specificities of antineutrophilcyto-plasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. *Clin. Nephrol*; 47: 1-5.
- Asanuma, Y., Oeser, A., Shintani, A.K., Turner, E., Olsen, N. and Fazio, S. (2003):** Premature coronary-artery atherosclerosis in systemic lupus erythematosus. *N. Engl. J. Med*; 349(25): 2407-2415.
- Austin, H.A. III., Klippel, J.H., Balow, J.E., le Riche, N.G., Steinberg, A.D. and Plotz, P.H. (1986):** Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. *N. Engl. J. Med*; 314(10): 614-619.
- Austin, H.A. III., Boumpas, D.T., Vaughan, E.M. and Balow, J.E. (1995):** High-risk Features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. *Nephrol. Dial. Transplant*; 10(9): 1620-1628.
- Baldwin, D.S. (1977):** Poststreptococcal glomerulonephritis. *Am. J. Med*; 62: 1
- Baldwin, D.S., Gluck, M.C. and Schacht, R.G. (1974):** The long - term course of poststreptococcal glomerulonephritis. *Ann. Intern. Med*; 80: 342-358.
- Balow, J.E., Boumpas, D.T., Fessler, B.J. and Austin, H.A. 3 rd. (1996):** Management of lupus nephritis. *Kidney Int. Suppl* 53: S88-S92.

- Balter, S., Benin, A., Pinto, S.W. (2000):** Epidemic nephritis in Nova Serrana, Brazil. *Lancet*; 355: 1776-1780.
- Baqi, N., Moazami, S., Singh, A., Ahmad, H., Balachandra, S. and Tejani, A. (1996):** Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. *J. Am. Soc. Nephrol*; 7(6): 924-929.
- Barber, C.E., Geldenhuys, L. and Hanly, G. (2006):** Sustained remission of lupus nephritis. *Lupus*; 15(2): 94-101.
- Barron, K.S., Person, D.A., Brewer, E.J.Jr., Beale, M.G. and Robson, A.M. (1982):** Pulse Methylprednisolone therapy in diffuse proliferative lupus nephritis. *J. Pediatr*; 101(1): 137-141.
- Bartosh, S.M., Fine, R.N. and Sullivan EK (2001):** Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. *Transplantation*; 72(5): 973-978.
- Batsford, S.R., Mezzano, S., Mihatsch, M., Schiltz, E. and Rodriguez-Iturbe B (2005):** Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPEB) or GAPDH? *Kidney Int*; 68 1120-1129.
- Becquet, O., Pasche, J., Gatti, H., Chenel, C., Abély, M., Morville, P. and Pietrement, C. (2010):** Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. *Pediatr. Nephrol*; Feb; 25(2): 275-80.
- Ben Maiz, H., Ben Moossa, F., Goucha, R., Abderrahim, E. and Kheder, A. (2006):** Acute post-infectious glomerulonephritis. *Nephrol. Ther*; 2(2): 93-105.

- Benito-Garcia, E., Schur, P.H. and Lahita, R. (2004):** Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. *Arthritis Rheum*; 51(6): 1030-1044.
- Berden, J.H. (1997):** Lupus nephritis. *Kidney Int*; 52(2): 538-558.
- Berge, A., Kihlberg, B.M., Sjöholm, A.G. and Björck, L. (1997).** Streptococcal protein H forms soluble complement-activating complexes with IgG, but inhibits complement activation by IgG-coated targets, *J. Biol. Chem*; 272 20774-20781.
- Berube, C., Mitchell, L., Silverman, E., David, M., Saint, Cyr. C. and Laxer, R. (1998):** The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. *Pediatr. Res*; 44(3): 351-356.
- Billal, D.S., Hotomi, M. and Yamauchi, K. (2004):** Macrolide-resistant genes of *Streptococcus pyogenes* isolated from the upper respiratory tract by polymerase chain reaction. *J. Infect. Chemother*; 10: 115-120.
- Blumenfeld, Z. (2007):** Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. *Minerva endocrinologica*; 32(1): 23-34.
- Blyth, C.C., Robertson, P.W. and Rosenberg, A.R. (2007):** Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review. *J. Paediatr. Child Health*. Jun; 43(6): 446-50.

Bono, L., Cameron, J.S. and Hicks, J.A. (1999): The long-term prognosis and complications of lupus nephritis and its treatment. QJM; 92(4): 211-218.

Borg, E.J., Horst, G., Hummel, E.J., Limburg, P.C. and Kallenberg, C.G. (1990): Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum; 33(5): 634-643.

Botto, M. and Walport, M.J. (2002): C1q autoimmunity and apoptosis. Immunobiology; 205: 395-406.

Botto, M., Dell'Agnola, C., Bygrave, A.E., Thompson, E.M., Cook, H.T. and Petry, F. (1998): Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet; 19(1): 56-59.

Boumpas, D. T., Austin, H. A., 3rd, Vaughn, E. M., Klippel, J. H., Steinberg, A.D. and Yarboro CH (1992): Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet; 340(8822): 741-745.

Boumpas, D.T., Furie, R., Manzi, S., Illei, G.G., Wallace, D.J. and Balow, J. E. (2003): A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum; 48(3): 719-727.

Bowness, P. (1994): Hereditary C1q deficiency and systemic lupus erythematosus. Q. J. Med; 87: 455-464.

- Brouhard, B.H., Travis, L.B. (1992):** Acute postinfectious glomerulonephritis. In: Edelman, C.M. (ed) Pediatric Kidney Disease; 1169-221.
- Brunner, H. I., Gladman, D. D., Ibañez, D., Urowitz, M. D. and Silverman, E. D. (2008):** Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. *Arthritis Rheum*; Feb; 58(2): 556-62.
- Bunnapradist, S., Chung, P., Peng, A., Hong, A., Chung, P. and Lee B (2006):** Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. *Transplantation*; 82(5): 612-618.
- Buratti, S., Szer, I. S., Spencer, C. H., Bartosh, S. and Reiff A (2001):** Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. *J. Rheumatol*; 28(9): 2103-2108.
- Cameron, J.S. (1994):** Lupus nephritis in childhood and adolescence. *Pediatr. Nephrol. (Berlin, Germany)*; 8(2): 230-249.
- Cameron, J.S. (1999):** Lupus nephritis. *J. Am. Soc. Nephrol*; 10(2): 413-424.
- Carapetis, J.R., Steer, A.C. and Mullholland, E.K. (2005):** The global burden of group A streptococcal diseases. *Lancet*; 5: 685-694.
- Cardinali, C., Caproni, M. and Fabbri, P. (1999):** The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. *Clin. Exp. Rheumatol*; 17(4): 427-432.

- Carreno, L., Lopez-Longo, F.J., Monteagudo, I., Rodriguez-Mahou, M., Bascones, M. and Gonzalez, C.M. (1999):** Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. *Lupus*; 8(4): 287-292.
- Cebul, D.R. and Poses, R.M. (1986):** The comparative cost-effectiveness of statistical decision rules and experienced physicians in pharyngitis management. *J. Am. Med. Assoc*; 256: 3353-3357.
- Cervera, R., Khamashta, M.A., Font, J., Sebastiani, G.D., Gil, A. and Lavilla, P. (2003):** Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine*; 82(5): 299-308.
- Chan, T.M., Li, F.K., Tang, C.S., Wong, R.W., Fang, G.X. and Ji, Y.L. (2000):** Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. *N. Engl. J. Med*; 343(16): 1156-1162.
- Churg, J., Bernstein, J. and Glassock, R.J. (1995):** Renal Disease: Classification and Atlas of Glomerular Diseases, 2nd Ed., New-York, Igaky-Shoin; 32(5): 320-330.
- Citera, G. and Wilson, W.A. (1993):** Ethnic and geographic perspectives in SLE. *Lupus*; 2(6): 351-353.
- Clynes, R., Dumitru, C. and Ravetch, J.V. (1998):** Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science (New York, NY)*; 279(5353): 1052-1054.

- Cohen, A.H., Nast, C.C., Adler, S.G. and Kopple, J.D. (1989):** Clinical utility of kidney biopsies in the diagnosis and management of renal disease. *Am. J. Nephrol*; 9: 309.
- Conlon, P.J., Fischer, C.A., Levesque, M.C., Smith, S.R., St Clair, E.W. and Allen, N.B. (1996):** Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. *Clin. Nephrol*; 46(3): 170-175.
- Contreras, G., Lenz, O., Pardo, V., Borja, E., Cely, C. and Iqbal, K. (2006):** Outcomes in African Americans and Hispanics with lupus nephritis. *Kidney Int*; 69(10): 1846-1851.
- Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E. and O’Nan, P. (2004):** Sequential therapies for proliferative lupus nephritis. *N. Engl. J. Med*; 350(10): 971-980.
- Contreras, G., Pardo, V. and Cely, C. (2005):** Factors associated with poor outcomes in patients with lupus nephritis. *Lupus*; 14: 890.
- Coremans, I.E.M. (1995):** Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. *Am. J. Kidney Dis*; 26: 595-601.
- Davidson, A., Diamond, B., Wofsy, D. and Daikh, D. (2005):** Block and tackle: CTLA4Ig takes on lupus. *Lupus*; 14(3): 197-203.
- Deocharan, B., Qing, X., Lichauco, J. and Putterman, C. (2002).** Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. *J. Immunol*; 168(6): 3072-3078.

- Donadio, J.V., Hart, G.M., Bergstralh, E.J. and Holley, K.E. (1995).** Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. *Lupus*; 4(2): 109-115.
- Dooley, M.A., Hogan, S., Jennette, C. and Falk, R. (1997):** Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. *Kidney Int*; 51(4): 1188 -1195.
- Eaton, R.B., Schnneider, G. and Schur, P.H. (1983):** Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. *Arthritis Rheum*; 26(1): 52-62.
- El Hachmi, M., Jadoul, M., Lefebvre, C., Depresseux, G. and Houssiau, F.A. (2003):** Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. *Lupus*; 12(9): 692-696.
- Emre, S., Bilge, I., Sirin, A., Kilicaslan, I., Nayir, A. and Oktem, F. (2001).** Lupus nephritis in children: prognostic significance of clinicopathological findings. *Nephron*; 87(2): 118-126.
- Euler, H.H. and Guillevin, L. (1994):** Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. *Annales de medicine interne*; 145(5): 296-302.
- Facklam, R. (2002):** What happened to the streptococci: overview of taxonomic and nomenclature changes. *Clin. Microbiol. Rev*; 15(4): 613-30.
- Faurschou, M., Starklint, H., Halberg, P. and Jacobsen, S. (2006):** Prognostic factors in lupus nephritis: diagnostic and therapeutic

delay increases the risk of terminal renal failure. J. Rheumatol; 33: 1563.

Flanc, R.S., Roberts, M.A., Strippoli, G.F., Chadban, S.J., Kerr, P.G. and Atkins, R.C. (2004): Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trials. Am. J. Kidney Dis; 43(2): 197-208.

Font, J., Cervera, R., Espinosa, G., Pallares, L., Ramos-Casals, M. and Jimenez, S. (1998): Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann. Rheum. Dis; 57(8): 456-459.

Fremaux-Bacchi, V., Noel, L.H. and Schifferli, J.A. (2002): No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol. Dial. Transplant; 17: 2041-2043.

Furie, R.A., Cash, J.M., Cronin, M.E., Katz, R.S., Weisman, M.H. and Aranow, C. (2001): Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol; 28(2): 257-265.

Galli, M., Finazzi, G., Norbis, F., Marziali, S., Marchioli, R. and Barbui, T. (1999): The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb. Haemost; 81(5): 695-700.

Gallo, G.R., Feiner, H.D. and Steele, J.M. Jr. (1980): Role of intrarenal vascular sclerosis in progression of poststreptococcal glomerulonephritis. Clin. Nephrol; 13: 449-457.

Gardner-Medwin, J.M., Dolezalova, P., Cummins, C. and Southwood, T.R. (2002): Incidence of Henoch-Schonlein purpura,

Kawasaki disease, and rare vasculitides in children of different ethnic origins. *Lancet*; 19; 360(9341): 1197-1202.

Gheissari, A., Adjodani, T.S., Hashemi, M., Mokhtarian, A. and Sirous, M. (2010): Outcome of Iranian children with mild post streptococcal glomerulonephritis. *Saudi. J. Kidney Dis. Transpl.* May; 21(3): 571-4.

Gigli, I., Sorvillo, J., Mecarelli-Halbwachs, L. and Leibowitch, J. (1981): Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. *J. Exp. Med*; 154: 1-12.

Ginzler, E., Diamond, H., Kaplan, D., Weiner, M., Schlesinger, M. and Seleznick, M. (1978): Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. *Arthritis Rheum*; 21(1): 37-44.

Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J. and Merrill, J.T. (2005): Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N. Engl. J. Med*; 353(21): 2219-2228.

Girardi, G. (2003): Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. *J. Clin. Invest*; 112: 1644-1654.

Gourley, M.F., Austin, H.A. 3rd, Scott, D., Yarboro, C.H., Vaughan, E.M. and Muir, J. (1996): Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. *Ann. Intern. Med*; 125(7): 5495-57.

Grootscholten, C., Ligtenberg, G., Hagen, E.C., van den Wall Bake, A.W., de Glas-Vos, J.W. and Bijl, M. (2006): Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. *Kidney Int*; 70(4): 732-742.

Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S.H., Henriksson, E.W. and van Vollenhoven, R.F. (2007): Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis Rheum*; 56(4): 1263-1272.

Hahn, B.H. (1998): Antibodies to DNA. *N. Engl. J. Med*; 338(19): 1359-1368.

Hari, P., Bagga, A., Mahajan, P. and Dinda, A. (2009): Outcome of lupus nephritis in Indian children. *Lupus*. Apr; 18(4): 348-54.

Harrington, D., Sutcliffe, I. and Chanter, N. (2002): The molecular basis of *Streptococcus equi* infection and disease. *Microbes Infect*; 4(4): 501-10.

Hiraki, L.T., Benseler, S.M. and Tyrrell, P.N. (2008): Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. *J. Pediatr*; 152: 550.

Hisano, S., Matsushita, M. and Fujita, T. (2007): Activation of the lectin complement pathway in post-streptococcal acute glomerulonephritis. *Pathol. Int*; 57: 351-357.

Hochberg, M.C. (1990): Systemic lupus erythematosus. *Rheum. Dis. Clin. Nam*; 16(3): 617-639.

Hochberg, M.C. (1997): Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*; 40(9): 1725.

Holers, V.M. and Thurman, J.M. (2004): The alternative pathway of complement in disease: opportunities for therapeutic targeting. *Mol. Immunol*; 41: 147-152.

Horak, P., Hermanova, Z. and Zadrazil, J. (2006): C1q complement component and -antibodies reflect SLE activity and kidney involvement. *Clin. Rheumatol*; 25: 532-536

Horii, Y., Iwano, M. and Hirata, E. (1993): Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. *Kidney Int*; 39(Suppl.): S71-S75.

Houssiau, F. (2007): Thirty years of cyclophosphamide: assessing the evidence. *Lupus*; 16(3): 212-216.

Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Sebastiani, G.D., Garrido, E.d., Ede, R. and Danieli, M.G. (2002): Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum*; 46(8): 2121-2131.

Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Sebastiani, G.D., de Ramon, Garrido, E. and Danieli, M.G. (2004): Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. *Arthritis Rheum*; 50(12): 3934-3940.

Ilowite, N.T. (2000): Premature atherosclerosis in systemic lupus erythematosus. *J. Rheumatol. Suppl*; 58: 15-19.

- Ishikawa, S., Segar, W.E., Gilbert, E.F., Burkholder, P.M., Levy, J.M. and Viseskul, C. (1978):** Myocardial infarct in a child with systemic lupus erythematosus. *Am. J. Dis. Child*; 132(7): 696-699.
- Ito, S., Kuriyama, H., Iino, N., Iguchi, S., Shimada, H., Ueno, M., Narita, I., Nakano, M., Nishi, S., Karasawa, R. and Gejyo, F. (2003):** Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist. *Clin. Exp. Nephrol.* Dec; 7(4): 290-300.
- Janeway, C.A., Travers, P., Walport, M. and Shlomcik, M. (2005):** Immunobiology: The Immune System In Health and Disease. 6th. ed. New York: Garland Science; 4: 570-593.
- Jesus, A.A., Silva, C.A., Carneiro-Sampaio, M., Sheinberg, M., Manguiera, C.L., Marie, S.K. and Liphaus, B.L. (2009):** Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. *Ann. N.Y. Acad. Sci.* Sep; 1173: 235-8.
- Johnston, F., Carapetis, J. and Patel, M.S. (1999):** Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. *Pediatr. Infec. Dis. J*; 18: 327-332.
- Jordan, S.C., Ho, W., Ettenger, R., Salusky, I.B. and Fine, R.N. (1987):** Plasma exchange Improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. *Pediatric nephrology (Berlin, Germany)*; 1(3): 276-280.
- Juncos, L.I. (2002):** Intrarenal mechanisms of salt and water retention in the nephritic syndrome. *Kidney Int*; 61: 1182-1195.

Kalaaji, M., Fenton, K.A., Mortensen, E.S., Olsen, R., Sturfelt, G. and Alm, P. (2007): Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. *Kidney Int*; 71(7): 664-672.

Kalaaji, M., Mortensen, E., Jorgensen, L., Olsen, R., Rekvig, O.P. (2006): Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. *Am. J. Pathol*; 168(6): 1779-1792.

Kalled, S.L., Cutler, A.H., Datta, S.K. and Thomas, D.W. (1998): Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. *J. Immunol*; 160(5): 2158-2165.

Kallenberg, C.G.M. (2008): Anti-C1qAutoantibodies. *Autoimmun. Rev*; 7: 612-615.

Karassa, F.B., Trikalinos, T.A. and Ioannidis, J.P. (2002): Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. *Arthritis Rheum*; 46(6): 1563-1571.

Karrar, A., Sequeira, W. and Block, J.A. (2001): Coronary artery disease in systemic lupus erythematosus: A review of the literature. *Semin Arthritis Rheum*; 30(6): 436-443.

Katsifis, G.E. and Tzioufas, A.G. (2004): Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. *Lupus*; 13(9): 673-678.

Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H. and Cosimi, A.B. (2000): Thromboembolic complications after treatment with

monoclonal antibody against CD40 ligand. *Nat. Med*; 6(2): 114.

Kimberly, R.P., Lockshin, M.D., Sherman, R.L., McDougal, J.S., Inman, R.D. and Christian, C.L. (1981): High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. *Am. J. Med*; 70(4): 817-824.

Kim, S.W., Frøkiaer, J. and Nielsen, S. (2007): Pathogenesis of oedema in nephritic syndrome: role of epithelial sodium channel. *Nephrology* ; 12 (Suppl.) 3: S8-S10.

Kingdon, E.J., McLean, A.G., Psimenou, E., Davenport, A., Powis, S.H. and Sweny, P. (2001): The safety and efficacy of MMF in lupus nephritis: a pilot study. *Lupus*; 10(9): 606-611.

Koike, T. (2000): Antiphospholipid antibodies in arterial thrombosis. *Ann. Med*; 32 Suppl. 1: 27-31.

Korb, L.C., Ahearn, J.M. (1997): C1q binds directly and specifically to surface Blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. *J. Immunol*; 158 (10): 4525 -4528.

Korbet, S.M., Lewis, E.J., Schwartz, M.M., Reichlin, M., Evans, J. and Rohde, R.D. (2000): Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. *Am. J. Kidney Dis*; 35(5): 904-914.

Korbet, S.M., Schwartz, M.M., Evans, J. and Lewis, E.J. (2007). Severe lupus nephritis: racial differences in presentation and outcome. *J. Am. Soc. Nephrol*; 18: 244.

- Koroleva, I.V., Sjöholm, A.G., Schalén, C. (1998):** Binding of complement subcomponent C1q to *Streptococcus pyogenes*: evidence for interactions with the M5 and FcRA76 proteins. FEM-S Immunol. Med. Microbiol. Jan; 20(1): 11-20.
- Kozyro, I., Korosteleva, L., Chernoshej, D., Danner, D., Sukalo, A. and Trendelenburg, M. (2008):** Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin. Immunol. Sep; 128 (3): 409-14.
- Kozyro, I., Perahudb, I. and Sadallah, S. (2006):** Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics; 117(5): 1663-1668
- Kremer, J.M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R. and Steinfeld, S. (2003):** Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med; 349(20): 1907-0915.
- Lachmann, P.J. and Hughes-Jones, N.C. (1984):** Initiation of complement activation. Springer Semin. Immunopathol; 7: 143-162.
- Leandro, M.J., Edwards, J.C., Cambridge, G., Ehrenstein, M.R. and Isenberg, D.A. (2002):** An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum; 46(10): 2673-2677.
- LeBlanc, B.A., Urowitz, M.B. and Gladman, O.D. (1994):** Serologically active, clinically quiescent systemic lupus erythematosus longterm follow up. J. Rheumatol; 21(1): 174-175.

Lee, H.S., Mujais, S.K., Kasinath, B.S., Spargo, B.H. and Katz, A.I. (1984). Course of renal pathology in patients with systemic lupus erythematosus. *Am. J. Med*; 77(4): 612-620.

Levey, A.S., Lan, S.P., Corwin, H.L., Kasinath, B.S., Lachin, J. and Neilson, E.G. (1992): Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. *Ann. Intern. Med*; 116(2): 114-123.

Lewis, E.J., Hunsicker, L.G., Lan, S.P., Rohde, R.D., Lachin, J.M. (1992): A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. *N. Engl. J. Med*; 326(21): 1373-1379.

Lim, C.S., Chin, H.J., Jung, Y.C., Kim, Y.S., Ahn, C. and Han, J.S. (1999): Prognostic factors of diffuse proliferative lupus nephritis. *Clin. Nephrol*; 52(3): 139-147.

Liszewski, M.K., Farries, T.C., Lublin, D.M., Rooney, I.A. and Atkinson, J.P. (1996): Control of the complement system. *Adv. Immunol*; 61: 201-283.

Luo, C., Chen, D., Tang, Z., Zhou, Y., Wang, J. and Liu, Z. (2010): Clinicopathological features and prognosis of Chinese patients with acute post-streptococcal glomerulonephritis. *Nephrology (Carlton)*. Sep; 15(6): 625-31.

Magil, A.B., Puterman, M.L., Ballon, H.S., Chan, V., Lirenman, D.S. and Rae, A. (1988): Prognostic factors in diffuse proliferative lupus glomerulonephritis. *Kidney Int.* Oct; 34(4): 511-517.

Manger, K., Wildt, L., Kalden, J.R. and Manger, B. (2006): Prevention of gonadal toxicity and preservation of gonadal function and

fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. *Autoimmun. Rev*; 5(4): 269-272.

Mannik, M., Wener, M.H. (1997): Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. *Arthritis Rheum*; 40: 1504-1511.

Marks, S.D., Sebire, N.J., Pilkington, C. and Tullus, K. (2007): Clinicopathological correlations of paediatric lupus nephritis. *Pediatr Nephrol. (Berlin, Germany)*; 22(1): 77-83.

McCurdy, D.K., Lehman, T.J., Bernstein, B., Hanson, V., King, K.K. and Nadorra, R. (1992): Lupus nephritis: prognostic factors in children. *Pediatrics*; 89(2): 240-246.

McDermott, E.M. and Powell, R.J. (1996): Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. *Ann. Rheum. Dis*; 55(4): 224-229.

McIsaac, W.J., White, D. and Tannenbaum, D. (1998): A clinical score to reduce unnecessary antibiotic use in patients with sore throat. *Can. Med. Assoc. J*; 158: 75-83.

Mezzano, S., Burgos, M.E. and Olavarri'a, F. (1997): Immunohistochemical localization of IL-8 and TGF-beta in streptococcal glomerulonephritis. *J. Am. Soc. Nephrol*; 8: 234-241.

Mitchell, D.A. (1999): C1q protects against the development of glomerulonephritis independently of C3 activation. *J. Immunol*; 162: 5676-5679.

Mitchell, D.A. (2002): C1q deficiency and autoimmunity: the effects of genetic background on disease expression. *J. Immunol*; 168: 2538-2543.

Mok, C.C., Lau, C.S. and Wong, R.W. (1998): Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. *Arthritis Rheum*; 41(5): 831-837.

Mok, C.C., Ying, K.Y., Tang, S., Leung, C.Y. and Lee, K.W. (2004): Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. *Arthritis Rheum*; 50(8): 2559-2568.

Monova, D., Monov, S. and Rosenova, K. (2002): Autoantibodies against Clq: view on association between systemic lupus erythematosus disease manifestation and C1q autoantibodies. *Ann. Rheum. Dis*; 61: 563-564

Montseny, J.J., Meyrier, A. and Kleinknecht, D. (1995): The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. *Medicine (Baltimore)*; 74: 63-73.

Moroni, G., Quaglini, S., Maccario, M., Banfi, G. and Ponticelli, C. (1996): “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. *Kidney Int*; 50(6): 2047-2053.

Moroni, G., Tantardini, F., Gallelli, B., Quaglini, S., Banfi, G. and Poli, F. (2005): The long-term prognosis of renal transplantation in patients with lupus nephritis. *Am. J. Kidney Dis*; 45(5): 903-911.

Muller-Eberhard, H.J. (1988): Molecular organization and function of the complement system. *Ann. Rev. Biochem*; 57: 321-347.

- Najafi, C.C., Korbet, S.M., Lewis, E.J., Schwartz, M.M., Reichlin, M. and Evans, J. (2001):** Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. *Kidney Int*; 59(6): 2156-2163.
- Nordstrand, A., Norgren, M. and Holm, S.E. (1999):** Pathogenic mechanism of acute post-streptococcal glomerulonephritis, *Scand. J. Infect. Dis*; 31: 523-537.
- Oda, T., Yamakami, K., Omasu, F., Suzuki, S., Miura, S., Sugisaki, T. and Yoshizawa, N. (2005):** Glomerular plasmin-like activity in relation to nephritis -associated plasmin receptor in acute post-streptococcal glomerulonephritis *J.Am.Soc.Nephrol*; 16: 247-254.
- Ognenovski, V.M., Marder, W., Somers, E.C., Johnston, C.M., Farrehi, J.G. and Selvaggi, S.M. (2004):** Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. *J. Rheumatol*; 31(9): 1763-1767.
- Ong, L.M., Hooi, L.S., Lim, T.O., Goh, B.L., Ahmad, G. and Ghazalli, R. (2005):** Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. *Nephrology (Carlton)*; 10(5): 504-510.
- Parra, G., Platt, J.L. and Falk, R.J. (1984):** Cell populations and membrane attack complex in glomeruli and patients with poststreptococcal glomerulonephritis: identification using monoclonal antibodies by indirect immunofluorescence. *Clin. Exp. Immunol. Immunopathol*; 33: 324-332.

- Parra, G., Rodri'guez-Iturbe, B. and Batsford, S. (1998):** Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study. *Kidney Int*; 54: 509-517.
- Parra, G., Romero, M. and Henri'quez-LaRoche, C. (1994):** Expression of adhesion molecules in poststreptococcal glomerulonephritis. *Nephrol. Dial. Transplant*; 9: 1412-1414.
- Paton, N.I., Cheong, I.K., Kong, N.C. and Segasothy, M. (1996):** Risk factors for infection In Malaysian patients with systemic lupus erythematosus. *QJM*; 89 (7): 531-538.
- Pedreanez A, Viera N, Rincon J, Mosquera J (2006):** Increased IL - 6 in supernatant of rat mesangial cell cultures treated with erythrogein toxin type B and its precursor isolated from nephritogenic streptococci. *Am. J. Nephrol*; 26: 75-81.
- Perez-Caballero, D., Garcia-Laorden, I. and Cortes, G. (2004):** Interaction between complement regulators and *Streptococcus pyogenes*: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involve two different cell surface molecules. *J. Immunol*; 173: 6899-6904.
- Perfumo, F. and Martini, A. (2005):** Lupus nephritis in children. *Lupus*; 14: 83-88
- Petri, M. (1998):** Infection in systemic lupus erythematosus. *Rheum. Dis. Clin. North Am*; 24(2): 423-456.
- Pisetsky, D.S. (2000):** Anti-DNA and autoantibodies. *Curr Opin Rheumatol*; 12(5): 364-368.

- Platt, J.L., Burke, B.A., Fish, A.J., Kim, Y. and Michael, A.F. (1982):** Systemic lupus erythematosus in the first two decades of life. Am. J. Kidney Dis; 2(1 Suppl.1): 212-222.
- Ponticelli, C. (1997):** Treatment of lupus nephritis the advantages of a flexible approach. Nephrol. Dial. Transplant; 12(10): 2057-2059.
- Ponticelli, C. and Moroni, G. (1998):** Renal biopsy in lupus nephritis-what for, when and how often? Nephrol Dial Transplant; 13(10): 2452-2454.
- Potlukova, E. and Kralikova, P. (2008):** Complement component C1q and Anti-C1q Antibodies in Theory and in Clinical Practice. Scand. J. Immunol; 5: 423-430
- Potter, E.V., Lipschultz, S.A. and Abidh, S. (1982):** Twelve to seventeen-year follow up of patients with acute post-streptococcal glomerulonephritis in Trinidad. N. Engl. J. Med; 307: 725-729.
- Pryor, B.D., Bologna, S.G. and Kahl, L.E. (1996):** Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum; 39(9): 1475-1482.
- Quigg, R.J. (2004):** Complement and autoimmune glomerular diseases. Curr. Dir. Autoimmun; 7: 165-180.
- Qushmaq, K., Esdaile, J. and Devine, D.V. (1999):** Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res; 12(3): 212-219.

- Rammelkamp, C.H., Weaver, R.S. and Dingle, J.H. (1952):** Significance of the epidemiologic differences between acute nephritis and acute rheumatic fever. Trans. Assoc. Am. Physicians; 65: 168-175.
- Ravelli, A., Wisnieski, J.J. and Ramenghi, B. (1997):** IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin. Exp. Rheumatol; 15: 215-219.
- Richter, S.S., Heilmann, K.P. and Beekmann, S.E. (2005):** Macrolide-resistant *Streptococcus pyogenes* in the United States, 2002-2003. Clin. Infect. Dis; 41: 599-608.
- Richter, S.S., Heilmann, K.P. and Dohrn, C.L. (2008):** Increasing erythromycin resistance among *Streptococcus pyogenes* in Europe. J. Antimicrob. Chemother; 61: 603-611.
- Rodriguez - Iturbe, B. (1984):** Epidemic poststreptococcal glomerulonephritis (Nephrology Forum). Kidney Int; 25: 129-136.
- Rodriguez - Iturbe, B. and Batsford, S. (2007):** Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet, Kidney Int; 71: 1094-1104.
- Rodriguez-Iturbe, B. and Musser, J.M. (2008):** The current state of post-streptococcal glomerulonephritis. J. Am. Soc. Nephrol; 61: 164-174.
- Rodri'guez-Iturbe, B., Herrera-Acosta, J. and Johnson, R.J. (2002):** Interstitial inflammation, sodium retention, and the pathogenesis of nephritic edema: a unifying hypothesis. Kidney Int; 62: 1379-1384.

Rodriguez-Iturbe, B., Rubio, L. and Garcia, R. (1981): Attack rate of post-streptococcal glomerulonephritis in families. A prospective study. *Lancet*; 1: 401-403.

Rood, M.J., ten Cate, R., van Suijlekom - Smit, L.W., den Ouden, E.J., Ouwerkerk, F.E. and Breedveld, F.C. (1999): Childhood-onset systemic lupus erythematosus: clinical presentation and prognosis in 31 patients. *Scand. J. Rheumatol*; 28(4): 222-226.

Ryan, K.J. and Ray, C.G. (2004): Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN 0-8385-8529-9.

Salah, S., Lotfy, H.M., Sabry, S.M., El Hamshary, A. and Taher, H. (2009): Systemic lupus erythematosus in Egyptian children. *Rheumatol. Int.* Oct; 29(12): 1463-8.

Salmon, J.E. and Roman, M.J. (2001): Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. *Curr. Opin. Rheumatol*; 13(5): 341-344.

Schiffer, L., Bethunaickan, R., Ramanujam, M., Huang, W., Schiffer, M. and Tao, H. (2008): Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. *J. Immunol*; 180(3): 1938-1947.

Schwartz, M.M. (2007): The pathology of lupus nephritis. *Semin Nephrol*; 27(1): 22-34.

Schwartz, M.M., Lan, S.P., Bernstein, J., Hill, G.S., Holley, K. and Lewis, E.J. (1992): Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. *Kidney Int*; 42 (3): 743-748.

- Segal, D. and Earle, D.P. (1941):** A consideration of certain biological differences between glomerulonephritis and rheumatic fever. *Am. J. Med. Sci*; 201: 528-539.
- Sekine, H., Kinser, T.T., Qiao, F., Martinez, E., Paulling, E., Ruiz, P., Gilkeson, G.S. and Tomlinson, S. (2011):** The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. *Arthritis Rheum*; Jan 10 [Epub ahead of print]
- Sesso, R. and Pinto, S.W.L. (2005):** Five-year follow-up of patients with epidemic glomerulonephritis due to *Streptococcus zooepidemicus*. *Nephrol. Dial. Transplant*; 20: 1808-1813.
- Sfikakis, P.P., Boletis, J.N., Lionaki, S., Vigklis, V., Fragiadaki, K.G. and Iniotaki, A. (2005):** Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. *Arthritis Rheum*; 52 (2): 501-513.
- Sfikakis, P.P., Boletis, J.N. and Tsokos, G.C. (2005):** Rituximab anti-B cell therapy in systemic lupus erythematosus: pointing to the future. *Curr. Opin. Rheumatol*; 17(5): 550-557.
- Siebert, C.E., Daha, M.R., Tseng, C.M., Coremans, I.E., van Es, L.A. and Breedveld, F.C. (1993):** Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. *Ann. Rheum Dis*; 52 (12): 851-856.
- Smeenk, R., Brinkman, K., van den Brink, H., Termaat, R.M., Berden, J. and Nossent, H. (1990):** Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. *Clin. Rheumatol*; 9(1 Suppl.1): 100-110.

- Sorger, K., Gessler, M. and Hu"bner, F.K. (1987):** Follow-up studies of three subtypes of acute postinfectious glomerulonephritis ascertained by renal biopsy. Clin. Nephrol; 27: 111-124.
- Soto, H.M., Parra, G. and Rodri'guez-Iturbe, B. (1997):** Circulating levels of cytokines in poststreptococcal glomerulonephritis. Clin. Nephrol; 47: 6-12.
- Spronk, P.E., Limburg, P.C. and Kallenberg, C.G. (1995):** Serological markers of disease activity in systemic lupus erythematosus. Lupus; 4(2): 86-94.
- Steer, A.C., Danchin, M.H. and Carapetis, J.R. (2007):** Group A streptococcal infections in children. J. Paediatric Child Health; 43(4): 203-213
- Steinberg, A.D. and Steinberg, S.C. (1991):** Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum; 34(8): 945-950.
- Svenungsson, E., Jensen-Urstad, K., Heimbürger, M., Silveira, A., Hamsten, A. and de Faire, U. (2001):** Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation; 104 (16): 1887-1893.
- Symmons, D.P. (1995):** Frequency of lupus in people of African origin. Lupus; 4(3): 176-178.
- Tamayo, J., Pe'rez-Trallero, E. and Go'mez-Garce's, J.L. (2005):** Resistance to macrolides, clindamycin and erythromycin in Streptococcus pyogenes isolated in Spain during 2004. J. Antimicrob. Chemother; 56: 780-782.

- Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J. and Rothfield, N.F. (1982):** The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*; 25(11): 1271-1277.
- Tejani, A. and Ingulli, E. (1990):** Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. *Nephron*; 55: 1.
- Temple, M.E. and Nahata, M.C. (2000):** Treatment of pediatric hypertension. *Pharmacotherapy*; 20: 140.
- Them, A., Stenberg, L. and Dahback, B. (1995):** Ig-binding surface proteins of *Streptococcus pyogenes* also bind human C4b-binding protein (C4bP), a regulatory component of the complement system. *J. Immunol*; 154: 375-386.
- Thongboonkerd, V., Luengpailin, J., Cao, J., Pierce, W.M., Cai, J., Klein, J.B. and Doyle, R.J. (2002):** Fluoride exposure attenuates expression of *Streptococcus pyogenes* virulence factors. *J. Biol. Chem*; 277: 16599-16605.
- Trager, J. and Ward, M.M. (2001):** Mortality and causes of death in systemic lupus erythematosus. *Curr. Opin. Rheumatol*; 13(5): 345-351.
- Trendelenburg, M. (2006):** High Prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. *Nephrol Dial Transplant*; 21: 3115-3121
- Trouw, L.A. (2004):** Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q containing immune complexes. *J. Clin. Invest*; 114: 679-688.

Uwatoko, S. and Mannik, M. (1988): Low-molecular weight C1q binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. *J. Clin. Invest*; 82: 816-824.

Vigna-Perez, M., Hernandez-Castro, B., Paredes-Saharopulos, O., Portales-Perez, D., Baranda, L. and Abud-Mendoza, C. (2006): Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. *Arthritis Res. Ther*; 8(3): R83.

Vogt, A., Schmiedeke, T. and Stockl, F. (1990): The role of cationic proteins in the pathogenesis of immune complex glomerulonephritis. *Nephrol. Dial. Transplant*; 5(Suppl.1): 6-9.

Von Muhlen, C.A. and Tan, E.M. (1995): Autoantibodies in the diagnosis of systemic rheumatic diseases. *Semin. Arthritis Rheum*; 24(5): 323-358.

Waldman, M. and Appel GB (2006). Update on the treatment of lupus nephritis. *Kidney Int*; 70: 1403.

Walsh, M., James, M., Jayne, D., Tonelli, M., Manns, B.J. and Hemmelgarn, B.R. (2007): Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. *Clin. J. Am. Soc. Nephrol*; 2(5): 968-975.

Ward, M.M. (2000): Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. *Kidney Int*; 57(5): 2136-2143.

Webb, K.H., Needham, C.A. and Kurtz, S.R. (2000). Use of a high-sensitivity rapid strep test without culture confirmation of negative results: 2 years' experience. *J. Fam. Prac*; 49: 34-36.

- Weening, J.J., D'Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E. and Appel, G.B. (2004):** The classification of glomerulonephritis in systemic lupus erythematosus revisited. *J. Am. Soc. Nephrol*; 15(2): 241-250.
- Wener, M.H. (2007):** Autoantibodies to C1q. In: Shoenfeld, Y., Gershwin, M.E. and Meroni, P.L. (eds) *Autoantibodies*. 2nd ed. Oxford: Elsevier Academic Press; 703-711
- White, A.V., Hoy, W.E. and McCredie, D.A. (2001):** Childhood poststreptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. *Med. J. Austral*; 174: 492-494.
- Willems, M., Haddad, E., Niaudet, P., Kone-Paut, I., Bensman, A. and Cochat, P. (2006):** Rituximab therapy for childhood-onset systemic lupus erythematosus. *J. Pediatr*; 148(5): 623-627.
- Wisniewski, J.J. and Naff, G.B. (1989):** Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. *Arthritis Rheum*; 32: 1119-1127.
- Wu, F.Q., Zhao, Q., Cui, X.D. and Zhang, W. (2009):** C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus. *Rheumatol. Int. Dec*; 23. [Epub ahead of print]
- Wyatt, R.J., Forristal, J., West, C.D., Sugimoto, S. and Curd, J.G. (1988):** Complement profiles in acute poststreptococcal glomerulonephritis. *Pediatr. Nephrol*; 2: 219-223.
- Yang, L.Y., Chen, W.P. and Lin, C.Y. (1994):** Lupus nephritis in children-a review of 167 patients. *Pediatrics*; 94(3): 335-340.

- Yokohama, H., Takaeda, M. and Wada, T. (1997):** Glomerular ICAM-1 expression related to circulating TNF-alpha in human glomerulonephritis. *Nephron*; 76: 425-433.
- Yoshizawa, N., Yamakami, K. and Fujino, M. (2004):** Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis: characterization of the antigen and associated immune response. *J. Amer. Soc. Nephrol*; 15: 1785-1793.
- Yu, M.C., Yu, M.S., Yu, M.K., Lee, F. and Huang, W.H. (2011):** Acute reversible changes of brachial-ankle pulse wave velocity in children with acute poststreptococcal glomerulonephritis. *Pediatr. Nephrol*; Feb; 26(2): 233-9.
- Zandman-Goddard, G., Levy, Y. and Shoenfeld, Y. (2005):** Intravenous immunoglobulin therapy and systemic lupus erythematosus. *Clin. Rev. Allergy Immunol*; 29(3): 219-228.
- Zimmerman, R., Radhakrishnan, J., Valeri, A. and Appel, G. (2001):** Advances in the treatment of lupus nephritis. *Annu. Rev. Med*; 52: 63-78.
- Zoch-Zwierz, W., Wasilewska, A. and Biernacka, A. (2001):** The course of poststreptococcal glomerulonephritis depending on methods of treatment of the preceding respiratory tract infection. *Wiad Lek*; 54: 56-63.
- Zoja, C., Benigni, A., Noris, M., Corna, D., Casiraghi, F. and Pagnoncelli, M. (2001).** Mycophenolate mofetil combined with a cyclooxygenase-2-inhibitor ameliorates murine lupus nephritis. *Kidney international*; 60(2): 653-663.